Nilutamide
Specifications
63612-50-0CAS Number
624-700-6EC Number
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dioneIUPAC Name
C12H10F3N3O4Chemical Formula
317.22 g/molMolecular Weight
nilutamide; 63612-50-0; Anandron; Nilandron; 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione; Nilutamida; Nilutamidum; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione; RU-23908; RU 23908; 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin; DTXSID3034165; NSC-758683; 51G6I8B902; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione; 2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-; CHEBI:7573; DTXCID1014165; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione; Anadron; 2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-; RefChem:57769; L02BB02; NSC684588; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazoline-3,5-dione; 5,5-Dimethyl-3-(4-nitro-3-(trifluoro-methyl)phenyl)-2,4-imidazolidinedione; 624-700-6; C12H10F3N3O4; Nilandrone; MFCD00864670; Nilandron;RU 23908; CHEMBL1274; Nilutamidum [Latin]; Nilutamida [Spanish]; 2,4-Imidazolidinedione,5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-; NCGC00015754-08; CAS-63612-50-0; Nilutamide [USAN:INN:BAN]; 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)-phenyl)imidazolidine-2,4-dione; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-1,3-diazolidine-2,4-dione; Nilandron (TN); RU 23908-10; SR-01000076034; Nilutamide (USAN/INN); BRN 0841906; Anandron;; Nilutamide CRS; UNII-51G6I8B902; Nilutamide, solid; Nilutamide; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione; 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione; NilutamideRU23908; Nilutamide (Standard); Spectrum_001625; Tocris-1759; NILUTAMIDE [MI]; SpecPlus_000902; NILUTAMIDE [INN]; Prestwick0_000928; Prestwick1_000928; Prestwick2_000928; Prestwick3_000928; Spectrum2_001973; Spectrum3_001633; Spectrum4_000600; Spectrum5_001512; Lopac-N-8534; NILUTAMIDE [USAN]; NILUTAMIDE [VANDF]; N 8534; NILUTAMIDE [MART.]; NILUTAMIDE [USP-RS]; NILUTAMIDE [WHO-DD]; BIDD:PXR0177; Lopac0_000879; SCHEMBL12670; BSPBio_000836; BSPBio_003325; KBioGR_001100; KBioSS_002105; MLS002154066; BIDD:GT0683; DivK1c_006998; SPECTRUM1504152; SPBio_002125; SPBio_003015; BPBio1_000920; GTPL2864; Nilutamide - Bio-X trade mark; orb1224392; orb1310771; NILUTAMIDE [ORANGE BOOK]; SCHEMBL29351021; KBio1_001942; KBio2_002105; KBio2_004673; KBio2_007241; KBio3_002545; NILUTAMIDE [EP MONOGRAPH]; HMS1570J18; HMS1922F03; HMS2093A10; HMS2097J18; HMS2230E03; HMS3262P19; HMS3268C18; HMS3369I02; HMS3414N15; HMS3678N13; HMS3714J18; HMS5083B12; NILUTAMIDE [USP MONOGRAPH]; Pharmakon1600-01504152; Tox21 110213; Tox21_110213; Tox21_301589; Tox21_500879; BDBM50135912; CCG-39427; EBC-07883; HY-13702R; NSC758683; s4836; SBB067297; STK633161; AKOS005565152; AKOS025147305; Tox21_110213_1; AC-5260; DB00665; FN26218; LP00879; NSC 758683; SB19036; SDCCGSBI-0050854.P004; NCGC00015754-01; NCGC00015754-02; NCGC00015754-03; NCGC00015754-04; NCGC00015754-05; NCGC00015754-06; NCGC00015754-07; NCGC00015754-09; NCGC00015754-10; NCGC00015754-11; NCGC00015754-12; NCGC00015754-15; NCGC00015754-16; NCGC00015754-20; NCGC00015754-22; NCGC00025280-01; NCGC00025280-02; NCGC00025280-03; NCGC00025280-04; NCGC00025280-05; NCGC00025280-06; NCGC00025280-07; NCGC00025280-08; NCGC00255271-01; NCGC00261564-01; AS-14123; BN166184; HY-13702; SMR001233381; ST075550; SBI-0050854.P003; AB00053180; CS-0007719; EU-0100879; N1212; NS00015500; C08164; D00965; EN300-316458; AB00053180_07; F222918; L000759; Q3877030; SR-01000076034-1; SR-01000076034-3; SR-01000076034-5; SR-01000076034-6; SR-01000076034-9; BRD-K23566484-001-05-2; BRD-K23566484-001-09-4; BRD-K23566484-001-14-4; BRD-K23566484-001-15-1; Z2242164525; Nilutamide, European Pharmacopoeia (EP) Reference Standard; 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3'-trifluoromethyl-4'-nitrophenyl)4,4-dimethyl-imidazoline-2,5-dione; 1-(3'-trifluoromethyl-4'nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3'trifluoromethyl-4'-nitropheyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3-'trifluoromethyl-4'-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl imidazolidine-2,5-dione; 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazolidine-2,5-dione; 1-(3-trifluoromethyl-4-nitro-phenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-(3-trifluoromethyl-4-nitrophenyl)-4,4-dimethyl-imidazoline-2,5-dione; 1-3-Trifluoromethyl-4-nitrophenyl)-4,4-dimethylimidazoline- 2,5-dione; 5,5-Dimethyl-3-(4-nitro-3-trifluoromethyl-phenyl)-imidazolidine-2,4-dione; 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedion; 5,5-DIMETHYL-3-(.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-4-NITRO-M-TOLYL)HYDANTOIN; 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-imidazolidine-2,4-dioneSynonyms
